Novo Nordisk: new data for Icodec insulin
(CercleFinance.com) - Novo Nordisk presented data from the ONWARDS 2 phase 3 study, showing that 37% of adults with type 2 diabetes treated with icodec once-weekly insulin achieved HbA1c <7.
0%, without significant hypoglycaemia.
Once-weekly insulin would be a remarkable advance in insulin innovation, a lead investigator of the ONWARDS 2 study said, adding that it could enable people with type 2 diabetes to reduce the complexity and burden of treatment by reducing the number of basal insulin injections from 365 to 52 per year, without compromising blood glucose management.
The results reported by patients reinforce our belief that icodec insulin has the potential to become the ideal insulin for people starting treatment, Novo Nordisk added.
Little pulse in the stock today, though - it is down 1% an hour into trading.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
0%, without significant hypoglycaemia.
Once-weekly insulin would be a remarkable advance in insulin innovation, a lead investigator of the ONWARDS 2 study said, adding that it could enable people with type 2 diabetes to reduce the complexity and burden of treatment by reducing the number of basal insulin injections from 365 to 52 per year, without compromising blood glucose management.
The results reported by patients reinforce our belief that icodec insulin has the potential to become the ideal insulin for people starting treatment, Novo Nordisk added.
Little pulse in the stock today, though - it is down 1% an hour into trading.
Copyright (c) 2022 CercleFinance.com. All rights reserved.